OncoMatch/Clinical Trials/NCT07107230
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Is NCT07107230 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JNJ-95437446 for colorectal neoplasms.
Treatment: JNJ-95437446 — The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: EGFR mutational status testing required (testing required; no eligibility threshold specified)
local molecular testing to determine epidermal growth factor receptor (EGFR) mutational status for NSCLC
Required: KRAS mutation status testing required (testing required; no eligibility threshold specified)
local molecular testing to determine ... Kirsten rat sarcoma ... (KRAS/NRAS/BRAF) mutation status for CRC
Required: NRAS mutation status testing required (testing required; no eligibility threshold specified)
local molecular testing to determine ... neuroblastoma ras viral oncogene ... (KRAS/NRAS/BRAF) mutation status for CRC
Required: BRAF mutation status testing required (testing required; no eligibility threshold specified)
local molecular testing to determine ... v-raf murine sarcoma oncogene B1 (KRAS/NRAS/BRAF) mutation status for CRC
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
appropriate hematologic function within the required limits
Kidney function
appropriate renal function within the required limits
Liver function
appropriate hepatic function within the required limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- NEXT Oncology · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07107230 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require EGFR?
Yes, EGFR mutational status testing required is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation status testing required is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation status testing required is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify